Free shipping on all orders over $ 500

BSI-401

Cat. No. M2010
BSI-401 Structure
Size Price Availability Quantity
10mg USD 100  USD100 In stock
50mg USD 280  USD280 In stock
100mg USD 400  USD400 In stock
200mg USD 680  USD680 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

BSI-401 is a novel PARP-1 inhibitor with both oral bioavailability and strong antitumor potency. The IC50 of BSI-401 for all of the five pancreatic cancer cell lines was <15 μM. BSI-401 inhibits the growth of pancreatic cancer cells in vitro significantly. BSI-401 inhibits low-anchorage tumor cell colony formation. BSI-401 combined with oxaliplatin had potent synergistic antitumor activity (46 versus 132 days, P = 0.0063), and significantly (P = 0.0148) prevented acute oxaliplatin-induced neurotoxicity.

Chemical Information
Molecular Weight 317.04
Formula C9H4INO4
CAS Number 142404-10-2
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Melisi D, et al. Clin Cancer Res. Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity.

Related PARP Products
DSB-1522

DSB-1522 is a PARP1 inhibitor that can be used in tumor-related studies.

DM-5167

DM-5167 is a PARP1 inhibitor that can be used in studies related to triple negative breast cancer.

NMS-03305293

NMS-03305293 is a PARP inhibitor with high selectivity for PARP1 isoforms and low DNA capture effect, which specifically kills BRCA mutated tumor cells. In addition, NMS-03305293 can penetrate the blood-brain barrier and can be used in studies related to CNS tumors and brain metastatic tumors.

SNV1521

SNV1521 is a potential best-in-class (BIC), highly selective and CNS-permeable PARP1 inhibitor.

Basroparib

Basroparib is an orally active selective inhibitor of end-anchor polymerase (TNKS) and an inhibitor of ribose polymerase (PARP) with antitumor activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: BSI-401 supplier, PARP, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.